Skip to main content

Muscular Dystrophies clinical trials at UC Irvine

2 in progress, 0 open to eligible people

Showing trials for
  • Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

    Sorry, not accepting new patients

    The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

    Irvine, California and other locations

  • AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

    Irvine, California and other locations

Our lead scientists for Muscular Dystrophies research studies include .